GEN-MKT-18-7897-A
Mar 15, 2019 | Blogs, Life Science Research | 0 comments
Welcome to the second in a series of posts marking International Women’s Day, and our ongoing support of World Cancer Research Fund. This installment is a review by Dr. Jennifer Baker, of her work, that, with the help of a WCRF grant, is studying body size and its links to breast cancer. Dr. Baker, Lead Investigator at Denmark’s Frederiksberg Hospital, has a Ph.D. in Human Nutrition from Cornell University. Her research focuses on clinical epidemiology.
Missed the first post in this special series? You can still read Dawn Penner’s account of her successful breast-cancer treatment.
This is an exciting time in the lab as we get ready to start a comprehensive new study that seeks to understand how weight and body size, throughout a woman’s life, combine to collectively increase or decrease her risk of breast cancer. This is an important question, given that existing WCRF research has shown obesity impacts pre- and post-menopausal breast cancer differently:
A deep dive into decades-old data.
Our research will look at a number of events across a woman’s life from birth until old age, including how old she was at the onset of puberty, body size throughout her life, whether or not she has benign breast disease (non-cancerous lumps) or dense breast tissue (milk glands, milk ducts, and supportive tissue).
Where will we get all these data points? We’ll delve into the health records of more than 158,000 seven- to 13-year-old girls who were born between 1930 and 1992, and attended school in Copenhagen. Then, using government-issued identification numbers, we will electronically link those historical records to national health registers and studies that contain information on the women’s current body size, other lifestyle and health information, as well as diagnoses of benign breast disease, mammographic density and breast cancer in adulthood.
Saving more lives: The potential impact of this research.
By combining all this information, we’ll be able to see how body size over a lifetime, along with the other events, can predict whether a woman will be diagnosed with different subtypes of breast cancer, and her chances of surviving after a diagnosis.
Our research will help build a risk profile that can be used to guide preventive efforts, and direct further research into the mechanisms that increase a woman’s risk of breast cancer at specific points across her life.
As our research gets underway, we would like to take a moment to thank WCRF for helping to make this project possible, as well as SCIEX and its team for their invaluable and ongoing support of WCRF. Your contributions make a difference around the world every day.
Be sure to keep an eye out for our third and final International Women’s Day post. In it, dietitian Deborah Howland talks about how she uses WCRF’s Eat Well During Cancer guide to help her patients cope with common treatment side effects.
Are you interested in learning more about Dr. Baker’s research? Here’s where you can find more information >
Produced by certain moulds, thriving in crops such as grain, nuts and coffee, mycotoxins have contaminated agriculture and food production industries for a long time. To intensify the challenge, mycotoxins are resilient, not easily broken down and ensuring the safety of food supply chains requires comprehensive solutions and we are here to share those solutions with you.
Electron-Activated Dissociation (EAD) is transforming the fields of metabolomics and lipidomics by providing enhanced fragmentation techniques that offer deeper insights into molecular structures. In September, Technology Networks hosted a webinar, “Enhancing Mass-Based Omics Analysis in Model Organisms,” featuring Dr. Valentina Calabrese from the Institute of Analytical Sciences at the University of Lyon. Valentina shared her insights on improving omics-based mass spectrometry analysis for toxicology studies using model organisms, particularly in metabolomics and lipidomics. This blog explores the additional functionalities EAD offers, its benefits in untargeted workflows, its incorporation into GNPS and molecular networking, and the future role it could play in these scientific domains.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has gained significant attention in the clinical laboratory due to its ability to provide best-in-class sensitivity and specificity for the detection of clinically relevant analytes across a wide range of assays. For clinical laboratories new to LC-MS/MS, integrating this technology into their daily routine operations may seem like a daunting task. Developing a clear outline and defining the requirements needed to implement LC-MS/MS into your daily operations is critical to maximize the productivity and success of your clinical laboratory.
Posted by
You must be logged in to post a comment.
Share this post with your network